GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Myovant Sciences Ltd (NYSE:MYOV) » Definitions » Total Current Liabilities

Myovant Sciences (Myovant Sciences) Total Current Liabilities : $245.8 Mil (As of Dec. 2022)


View and export this data going back to 2016. Start your Free Trial

What is Myovant Sciences Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Myovant Sciences's total current liabilities for the quarter that ended in Dec. 2022 was $245.8

Myovant Sciences Total Current Liabilities Historical Data

The historical data trend for Myovant Sciences's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myovant Sciences Total Current Liabilities Chart

Myovant Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Total Current Liabilities
Get a 7-Day Free Trial 37.09 71.97 85.93 281.34 250.33

Myovant Sciences Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 269.04 250.33 226.24 251.69 245.75

Myovant Sciences Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Myovant Sciences's Total Current Liabilities for the fiscal year that ended in Mar. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=86.586+2.148
+Other Current Liabilities+Current Deferred Liabilities
=26.389+135.207
=250.3

Myovant Sciences's Total Current Liabilities for the quarter that ended in Dec. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=102.303+2.703
+Other Current Liabilities+Current Deferred Liabilities
=23.516+117.231
=245.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Myovant Sciences Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Myovant Sciences (Myovant Sciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Myovant Sciences Ltd (NYSE:MYOV) » Definitions » Total Current Liabilities
Comparable Companies
AXSM IMAB RVNC BBIO RXRX CRNX VTYX LYEL GRNA ARQT OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122
Traded in Other Exchanges
N/A
Address
11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB
Website
https://www.myovant.com
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
Executives
Sumitomo Chemical Co., Ltd. 10 percent owner 7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Lauren Merendino officer: Chief Commercial Officer C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David C Marek director, officer: Principal Executive Officer C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Matthew Lang officer: General Counsel & Corp. Secy. C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Ferreira Juan Camilo Arjona officer: Chief Medical Officer C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Uneek Mehra officer: Principal Financial Officer C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Shigeyuki Nishinaka director 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Nancy Valente director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Terrie Curran director C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Frank Karbe officer: Principal Fin'l & Accounting C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Kim Sablich officer: Chief Commercial Officer C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Hiroshi Nomura director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Sumitovant Biopharma Ltd. 10 percent owner C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd 10 percent owner 6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045
Adele M. Gulfo director ONE NEENAH CENTER, 4TH FLOOR, P.O. BOX 669, NEENAH WI 54957